Stress Relief Effect of Korean Red Ginseng

May 23, 2015 updated by: In Kyoon Lyoo, MD, PhD, MMS, Seoul National University Hospital

Effects of Korean Red Ginseng on Stress Relief and Cognitive and Mental Function Enhancement Using Neuroimaging: Double-Blind, Randomized, Placebo-Controlled Clinical Trial

The purpose of this study is to examine clinical and neuropsychiatric effects of Korean Red Ginseng and examine changes in brain structure, function and metabolites. A total of 60 healthy volunteers will be recruited and will be assigned to either Korean Red Ginseng group or placebo group. Individuals will be examined through clinical assessment, neuropsychological function tests and neuroimaging.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

51

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Seoul, Korea, Republic of, 110-744
        • Seoul National University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Ages between 18~65

Exclusion Criteria:

  • Current or past medical history, medical illnesses that are detected during clinical and physical evaluations
  • Current Axis 1 diagnosis or past history of schizophrenia, bipolar, or psychotic disorders assessed by SCID-IV
  • Current diagnosis of substance abuse assessed by SCID-IV
  • Taking or have taken psychiatric medication in the past 2 months
  • Head trauma accompanied by loss of consciousness or seizure
  • IQ 80 or below
  • Planning pregnancy, currently pregnant, or breastfeeding
  • Claustrophobia or other fMRI incompatible factors such as pace makers
  • Taking drugs, including over the counter drugs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Placebo Capsule (1g/day) for 8 Weeks
Experimental: Korean Red Ginseng
Korean Red Ginseng Capsule (1g/day) for 8 Weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change from Baseline in Stress Scores at 8 Weeks
Time Frame: Baseline and 8 Weeks
Baseline and 8 Weeks
Change from Baseline in Stress Scores at 4 Weeks
Time Frame: Baseline and 4 Weeks
Baseline and 4 Weeks
Change from Baseline in Stress Scores at 1 Week
Time Frame: Baseline and 1 Week
Baseline and 1 Week
Change from Baseline in Neurocognitive Function at 8 Weeks
Time Frame: Baseline and 8 Weeks
Baseline and 8 Weeks
Change from Baseline in Brain Function, Chemistry, and Structure Measured Using Magnetic Resonance Imaging at 8 Weeks
Time Frame: Baseline and 8 Weeks
Baseline and 8 Weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in Fatigue Scores at 8 Weeks
Time Frame: Baseline and 8 Weeks
Baseline and 8 Weeks
Change in Fatigue Scores at 4 Weeks
Time Frame: Baseline and 4 Weeks
Baseline and 4 Weeks
Change in Fatigue Scores at 1 Week
Time Frame: Baseline and 1 Week
Baseline and 1 Week
Change in Depressive Scores at 8 Weeks
Time Frame: Baseline and 8 Weeks
Baseline and 8 Weeks
Change in Depressive Scores at 4 Weeks
Time Frame: Baseline and 4 Weeks
Baseline and 4 Weeks
Change in Depressive Scores at 1 Week
Time Frame: Baseline and 1 Week
Baseline and 1 Week
Change in Anxiety Scores at 8 Weeks
Time Frame: Baseline and 8 Weeks
Baseline and 8 Weeks
Change in Anxiety Scores at 4 Weeks
Time Frame: Baseline and 4 Weeks
Baseline and 4 Weeks
Change in Anxiety Scores at 1 Week
Time Frame: Baseline and 1 Week
Baseline and 1 Week
Number of Participants Who Experienced Adverse Events
Time Frame: Week 1
Week 1
Number of Participants Who Experienced Adverse Events
Time Frame: Week 4
Week 4
Number of Participants Who Experienced Adverse Events
Time Frame: Week 8
Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2010

Primary Completion (Actual)

April 1, 2011

Study Completion (Actual)

April 1, 2011

Study Registration Dates

First Submitted

February 26, 2012

First Submitted That Met QC Criteria

February 26, 2012

First Posted (Estimate)

March 2, 2012

Study Record Updates

Last Update Posted (Estimate)

May 27, 2015

Last Update Submitted That Met QC Criteria

May 23, 2015

Last Verified

May 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • KG2010

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress Relief

Clinical Trials on Korean Red Ginseng

Subscribe